| Dr Joel T Dall, MD | |
|
1160 E 3900 S Ste 4050, Salt Lake City, UT 84124-1264 | |
| (801) 262-8486 | |
| (801) 284-8699 |
| Full Name | Dr Joel T Dall |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 34 Years |
| Location | 1160 E 3900 S Ste 4050, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992707657 | NPI | - | NPPES |
| D0651 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 275517-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Salt Lake Orthopaedic Specialist Llc | 3173422730 | 6 |
News Archive
A report from the University of Pennsylvania School of Medicine in Philadelphia says that black women in the US with a family history of breast or ovarian cancer, are far less likely to seek genetic counselling and possible testing than their white counterparts, and although the reasons for the disparity are not clear, it is suspected that mistrust of both the medical system and advice from primary physicians may be factors.
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
Across the University of Colorado at Boulder campus students are sharing answers, checking their responses to questions against those of their neighbors and making adjustments to those answers in hopes of earning a better grade.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
› Verified 5 days ago
| Entity Name | Alpine Management And Consulting |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427184449 PECOS PAC ID: 5496659245 Enrollment ID: O20031122000068 |
News Archive
A report from the University of Pennsylvania School of Medicine in Philadelphia says that black women in the US with a family history of breast or ovarian cancer, are far less likely to seek genetic counselling and possible testing than their white counterparts, and although the reasons for the disparity are not clear, it is suspected that mistrust of both the medical system and advice from primary physicians may be factors.
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
Across the University of Colorado at Boulder campus students are sharing answers, checking their responses to questions against those of their neighbors and making adjustments to those answers in hopes of earning a better grade.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
› Verified 5 days ago
| Entity Name | Salt Lake Orthopaedic Specialist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811913429 PECOS PAC ID: 3173422730 Enrollment ID: O20040102000837 |
News Archive
A report from the University of Pennsylvania School of Medicine in Philadelphia says that black women in the US with a family history of breast or ovarian cancer, are far less likely to seek genetic counselling and possible testing than their white counterparts, and although the reasons for the disparity are not clear, it is suspected that mistrust of both the medical system and advice from primary physicians may be factors.
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
Across the University of Colorado at Boulder campus students are sharing answers, checking their responses to questions against those of their neighbors and making adjustments to those answers in hopes of earning a better grade.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel T Dall, MD 280 S Main St, Bountiful, UT 84010-6236 Ph: (801) 505-0821 | Dr Joel T Dall, MD 1160 E 3900 S Ste 4050, Salt Lake City, UT 84124-1264 Ph: (801) 262-8486 |
News Archive
A report from the University of Pennsylvania School of Medicine in Philadelphia says that black women in the US with a family history of breast or ovarian cancer, are far less likely to seek genetic counselling and possible testing than their white counterparts, and although the reasons for the disparity are not clear, it is suspected that mistrust of both the medical system and advice from primary physicians may be factors.
A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
Across the University of Colorado at Boulder campus students are sharing answers, checking their responses to questions against those of their neighbors and making adjustments to those answers in hopes of earning a better grade.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
› Verified 5 days ago
James Tran, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: Rehab 85 N Medical Drive Rm 2122, Salt Lake City, UT 84132 Phone: 801-585-2589 | |
Dr. Chase K Hansen, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1121 E Brickyard Rd Apt 1803, Salt Lake City, UT 84106 Phone: 801-309-0848 | |
Michael Tobler, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6360 S 3000 E Ste 300, Salt Lake City, UT 84121 Phone: 385-900-5094 | |
Dr. Jeffrey G Randle, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1160 E 3900 S, #5000, Salt Lake City, UT 84124 Phone: 801-262-8486 Fax: 801-284-8699 | |
Dr. Michael Matthew Green, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 81 N Mario Capecchi Dr, Department Of Pediatrics, Salt Lake City, UT 84113 Phone: 801-213-7737 Fax: 801-587-7539 | |
Ms. Allison Oki, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Univerisity Of Utah, Department Of Pm&r, Salt Lake City, UT 84132 Phone: 801-585-2589 Fax: 801-587-7287 | |
Bradeigh Smithson Godfrey, D.O. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 258 Heritage Ctr, Salt Lake City, UT 84112 Phone: 801-587-1290 |